How is China's ampicillin production capacity restructuring affecting market supply?

How is China's ampicillin production capacity restructuring affecting market supply?
China's ampicillin-related capacity is undergoing strategic restructuring rather than simple expansion. A notable example is Shandong Lukang's relocation project for semi-synthetic penicillin and cephalosporin freeze-dried products, investing RMB 90.85 million. The project will retain 20 t/a of ampicillin sodium while adding piperacillin sodium (160 t/a) and mezlocillin sodium (50 t/a), keeping total capacity at 230 t/a. This shift reflects a deliberate move toward higher-value penicillins. Separately, in the veterinary space, Shandong Qihui Chemical is building 180 t/a of ampicillin sodium using enzymatic technology, part of a RMB 97 million project. These changes indicate a bifurcation: human-grade capacity is consolidating around specialized products, while veterinary-grade supply is expanding with enzyme-based processes, which could alter cost structures and price dynamics.